Small cell lung cancer research hub
21 indexed studies · 11 currently recruiting
- ongoing, recruitingHuman Pharmacology (Phase I)- Other
Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after platinum-based therapy.
This study is looking at a new treatment called Debio 0123 combined with standard chemotherapy for adults with a type of lung cancer called small cell lung cancer. Participants will have already had treatment that didn't stop their cancer from growing or coming back, and are looking for other options.
Spain - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - recruiting
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
This study, called TRACERx EVO, looks at how lung cancer and mesothelioma change during treatment. It involves collecting information and samples from patients with early or advanced disease to help doctors understand the illnesses better and find new ways to treat them.
United Kingdom - recruitingPHASE1, PHASE2
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
This study is testing new medicines, Gocatamig and Ifinatamab Deruxtecan (I-DXd), for advanced small cell lung cancer that has come back or isn't responding to treatment. Researchers want to see if these drugs, alone or together, are safe and can shrink the cancer.
United States · Argentina · Australia - active not recruitingPHASE3
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
This study looks at treating a specific type of advanced lung cancer. It compares two treatments, atezolizumab alone or combined with lurbinectedin, after initial chemotherapy. The aim is to see which approach works best to keep the cancer stable.
United States · Belgium · Germany - active not recruitingPHASE3
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This study looks at new treatments (Durvalumab, Tremelimumab) for a type of lung cancer, Small Cell Lung Cancer, after initial strong treatment. It aims to see if these drugs can stop the cancer from coming back.
United States · Argentina · Belgium - recruitingPHASE3
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
This study is looking at a new medicine called ifinatamab deruxtecan (I-DXd) for small cell lung cancer that has come back. It compares I-DXd to standard treatments to see if it works better and is safe.
United States · Australia · Austria - recruitingPHASE3
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
This study, called DLLEVATE, is looking at a new treatment, ZL-1310, for people with small cell lung cancer that has come back. It compares ZL-1310 to other standard treatments to see if it's safe and works well. You might be eligible if you're over 18 and have had previous treatments.
United States · China · Japan - active not recruiting
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.
Argentina · Austria · Belgium - active not recruiting
DOTATOC PET/CT for Imaging NET Patients
This study looks at a new type of scan called 68Ga-DOTATOC PET/CT for checking on neuroendocrine tumours (NETs) and similar growths. It compares it to a standard scan to see if it’s better at finding these conditions safely.
Canada - active not recruitingPHASE3
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
This study is looking at a new combination of medicines, tarlatamab and durvalumab, for people with advanced small-cell lung cancer. It wants to see if this combination helps people live longer compared to durvalumab alone, after their initial chemotherapy treatment.
United States · Argentina · Australia - authorisedTherapeutic confirmatory (Phase III)
DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.
This study looks at a new drug, obrixtamig, alongside usual treatment for extensive small cell lung cancer. It aims to see if this new combination helps people live longer and feel better compared to the usual treatment alone.
Czechia · Sweden · Poland - recruitingPHASE3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
This study looks at a new treatment combination for a type of advanced lung cancer called extensive stage small-cell lung cancer (ES-SCLC). It compares a combination including tarlatamab with a standard treatment to see if it helps people live longer.
United States · Argentina · Australia - recruiting
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
This study collects information from real-life lung cancer patients in Germany. It looks at how cancer is tested, treated, and how patients get on. The aim is to understand and improve care for lung cancer patients and see how different treatments affect them.
Germany - recruitingPHASE1, PHASE2
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
This study is testing a new drug, IDE849, for certain cancers including a type of lung cancer. It aims to see if it's safe and effective, sometimes using it alone and sometimes with other medicines.
United States · Australia · Brazil - active not recruitingPHASE2
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
This study is looking at a new treatment called BNT327 for tiny-cell lung cancer. It combines BNT327 with chemotherapy to see how safe and effective it is for people whose cancer is widespread or has come back after other treatments.
United States · Australia · South Korea - recruitingPHASE1
Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma
This study is looking into a new use for an existing medicine called acetazolamide, in combination with standard treatments for small cell lung cancer. Researchers want to see if it can help improve how well chemotherapy and radiotherapy work by affecting how cancer cells get their energy.
France · Monaco - active not recruitingPHASE3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
This study looks at a new drug, Tarlatamab, for people with a type of lung cancer called limited-stage small-cell lung cancer (LS-SCLC). It aims to see if Tarlatamab can help people live longer without their cancer getting worse after chemotherapy and radiotherapy.
United States · Argentina · Australia - recruiting
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
This study looks at people with specific cancers (pancreatic, lung, brain) who have lived unexpectedly long. By comparing them to others, researchers hope to find new ways to treat these difficult cancers and improve outcomes for future patients.
France - active not recruitingPHASE3
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
This study looks at new drug combinations for a type of lung cancer called Limited-Stage Small Cell Lung Cancer (LS-SCLC). Researchers want to see if adding pembrolizumab and olaparib to standard treatments helps people live longer.
United States · Australia · Belgium